rna
interfer
rnai
gener
signific
interest
strategi
suppress
viral
infect
case
antivir
activ
unmodifi
shortinterf
rna
sirna
attribut
activ
innat
immun
respons
hypothes
immunostimul
unmodifi
sirna
could
mediat
rnai
well
innat
immun
stimul
depend
mode
drug
deliveri
investig
potenti
immunostimulatori
rna
isrna
suppress
influenza
viru
vivo
mous
lung
lipidoid
formul
unmodifi
sirna
target
influenza
nucleoprotein
gene
exhibit
antivir
activ
formul
optim
increas
antivir
activ
antivir
activ
lipidoiddeliv
sirna
depend
sequenc
homolog
influenza
genom
sirna
direct
unrel
target
also
suppress
influenza
replic
vivo
activ
primarili
attribut
enhanc
innat
immun
stimul
lipidoidmedi
deliveri
indic
increas
tolllik
receptor
tlr
activ
sirna
certain
chemic
modif
sirna
backbon
block
activ
retain
vitro
rnai
activ
prevent
sirnamedi
antivir
activ
despit
enhanc
lipidoidmedi
deliveri
demonstr
innat
immun
activ
caus
unmodifi
sirna
therapeut
relev
effect
nonrnai
effect
control
chemic
modif
drug
deliveri
rna
interfer
rnai
mediat
short
doublestrand
rna
dsrna
molecul
term
shortinterf
rna
sirna
caus
degrad
target
mrna
highli
sequencespecif
manner
rnai
hold
signific
promis
antivir
therapeut
strategi
rna
virus
singleor
dsrna
genom
may
good
target
rnai
rnai
use
inhibit
varieti
difficulttocontrol
virus
human
immunodefici
viru
hepat
c
respiratori
tract
infect
respiratori
syncyti
viru
rsv
parainfluenza
viru
sever
acut
respiratori
syndrom
coronaviru
suppress
vivo
follow
intranas
instil
nake
sirna
case
nake
unmodifi
sirna
target
rsv
rnaimedi
mechan
action
confirm
detect
rsv
mrna
cleavag
site
lipid
carrier
also
use
deliv
sirna
effect
ebola
viru
dna
viru
hepat
b
ge
et
al
report
select
sirna
sequenc
effici
inhibit
influenza
viral
replic
cell
cultur
chicken
egg
promis
sirna
target
np
pa
gene
influenza
subsequ
use
ge
et
al
inhibit
influenza
vivo
mous
model
infect
report
inhibit
viral
titer
lung
mice
follow
intraven
deliveri
linear
poli
ethylenimin
pei
tompkin
et
al
use
sirna
sequenc
deliv
hydrodynam
intraven
inject
follow
intranas
instil
oligofectaminesirna
complex
demonstr
protect
lethal
challeng
multipl
differ
influenza
subtyp
includ
thoma
et
al
also
demonstr
effici
inhibit
influenza
mous
lung
use
differ
form
pei
deliveri
materi
report
green
fluoresc
protein
gfp
sequenc
use
control
nonspecif
effect
initi
thought
sirna
avoid
interferon
ifn
respons
observ
longer
dsrna
molecul
induct
intracellular
ifn
respons
thought
occur
long
dsrna
interact
cytosol
receptor
rna
melanoma
retino
acidinduc
genei
collect
term
retino
acidinduc
geneilik
helicas
activ
tolllik
receptor
tlr
howev
recent
appreci
sirna
shorter
length
certain
instanc
interact
ref
ref
ref
induc
ifn
respons
interact
sirna
tlr
depend
greatli
sirna
structur
sequenc
abrog
sequenc
select
strategi
andor
chemic
modif
sirna
chemic
modif
pyrimidin
purin
shown
prevent
ifn
respons
substitut
ribos
backbon
particular
shown
suppress
interact
immunostimulatori
rna
isrna
hypothes
modif
modul
bind
tlr
structur
conform
chang
affect
hydrogen
bond
minor
groov
dsrna
human
mice
interact
occur
mainli
endosom
special
cell
call
plasmacytoid
dendrit
cell
pdc
pdc
circul
blood
resid
larg
number
liver
chief
produc
mani
cell
type
includ
myeloid
dc
mdc
monocyt
monocytederiv
dc
modc
express
function
mice
human
cell
also
respond
immunostimulatori
sequenc
sirna
produc
cytokin
tumor
necrosi
high
amount
isrna
function
definit
may
determin
base
sequenc
structur
chemic
modif
also
locat
endosom
cell
sequenceand
structurespecif
tlr
interact
occur
system
ifn
respons
rna
may
confound
mask
genespecif
effect
true
rnai
vivo
model
viral
infect
previous
mention
rnaimedi
mechan
action
confirm
detect
rsv
mrna
cleavag
site
follow
dose
nake
unmodifi
sirna
howev
influenza
viru
highli
sensit
type
ifn
product
type
ifn
import
compon
innat
defens
influenza
virus
small
molecul
agonist
poli
cl
c
previous
shown
potent
vivo
antivir
activ
influenza
induct
ifn
respons
clinic
relev
use
sirna
requir
method
drug
deliveri
role
drug
deliveri
enhanc
isrna
activ
clearli
defin
hypothes
addit
mediat
rnai
sirna
may
antivir
effect
due
innat
immun
stimul
effect
may
modul
method
deliveri
recent
establish
combinatori
librari
lipidlik
materi
deliveri
nucleic
acid
term
lipidoid
effici
deliv
small
rna
across
cellular
barrier
use
highthroughput
screen
method
promis
novel
materi
previous
identifi
exhibit
highli
effici
vitro
vivo
deliveri
sirna
molecul
elicit
rnaimedi
downregul
liverspecif
target
investig
abil
sirna
deliv
one
promis
candid
materi
abil
suppress
influenza
viru
replic
lung
use
murin
model
influenza
infect
use
new
lipidoid
nanoparticl
formul
optim
achiev
antivir
effect
describ
effici
prophylact
inhibit
influenza
mous
lung
due
innat
immun
stimul
follow
deliveri
unmodifi
sirna
result
sirna
nanoparticl
antivir
activ
shortinterf
rna
encapsul
nanoparticl
base
upon
lipidoid
novel
lipidlik
materi
use
effici
vivo
sirnadeliveri
liver
figur
develop
method
gener
stabl
nanoparticl
lipidoid
cholesterol
polyethylen
glycol
peg
ceramid
sodium
acet
ethanol
lipidoid
formul
extrud
high
pressur
normal
particl
size
dialyz
remov
ethanol
particl
consist
exhibit
characterist
size
nm
measur
dynam
light
scatter
encapsul
rna
supplementari
tabl
investig
use
dialyz
lipidoid
nanoparticl
inhibit
strain
influenza
viru
mous
model
infect
initi
studi
formul
particl
complex
indic
dosedepend
respons
follow
prophylact
treatment
hour
infect
superleth
challeng
plaqueform
unit
influenza
viru
reduct
lung
viral
titer
compar
phosphatebuff
salin
pb
inject
observ
mgkg
dose
figur
howev
dialyz
lipidoid
particl
contain
also
exhibit
reduct
viral
titer
mgkg
commerci
avail
pei
comparison
demonstr
viral
titer
reduct
mgkg
dose
peisirna
nanoparticl
also
demonstr
inhibitori
effect
mgkg
dose
inhibit
viral
titer
effect
similar
data
shown
optim
particl
formul
vari
method
particl
prepar
upon
lyophil
reconstitut
pb
lipidoid
nanoparticl
increas
size
nm
supplementari
tabl
larger
particl
effici
nonlyophil
freshli
prepar
particl
suppress
influenza
viral
titer
supplementari
figur
extrus
particl
filter
result
similar
size
extrus
filter
data
shown
extrus
particl
filter
follow
dialysi
result
viral
suppress
effici
extrus
filter
follow
lyophil
compar
freshli
prepar
nanoparticl
lyophil
particl
slightli
increas
antivir
effect
mgkg
dose
lyophil
nanoparticl
mgkg
sirna
dose
reduc
viral
titer
figur
howev
highest
dose
lyophil
nanoparticl
caus
weight
loss
first
inject
second
inject
mgkg
dose
viral
titer
reduct
lyophil
particl
averag
compar
pb
figur
lyophil
formul
mgkg
dose
select
rest
studi
address
issu
sequenceindepend
inhibit
influenza
observ
particl
ad
scrambl
control
sequenc
experiment
set
sirna
lyophil
lipidoid
nanoparticl
formul
scrambl
also
investig
serum
ifn
respons
follow
dose
nanoparticl
sirna
sequenc
known
induc
ifn
respons
vivo
mice
vitro
human
cell
observ
associ
effici
suppress
viral
titer
supplementari
figur
activ
innat
immun
respons
supplementari
figur
use
scrambl
sequenc
addit
viral
inhibit
respons
irrelev
sirna
sequenc
known
induc
ifn
similar
magnitud
observ
target
flu
genom
similar
antivir
activ
observ
well
sequenc
sipolyau
one
strand
polya
strand
report
stimul
immun
respons
formul
dotap
tabl
antivir
activ
compar
sidebysid
lyophil
nanoparticl
surprisingli
sinp
sipolyau
lipidoid
particl
suppress
influenza
reproduct
equival
achiev
reduct
viral
titer
compar
pb
control
figur
contain
sinp
elicit
high
level
serum
neither
sigfpnanoparticl
pb
inject
gener
detect
level
serum
figur
effect
antivir
activ
chemic
modif
sirna
backbon
investig
modif
prevent
interact
tlr
sequenc
modifi
variou
backbon
nucleic
acid
substitut
tabl
immun
stimul
modifi
sirna
first
investig
vitro
transfect
modifi
sirna
cultur
human
peripher
blood
mononuclear
cell
pbmc
gene
porter
dotap
level
cultur
supernat
measur
enzymelink
immunosorb
assay
hour
transfect
figur
incorpor
neither
deoxythymidin
overhang
substitut
phosphorothio
linkag
abl
prevent
immun
stimul
substitut
hydroxyl
group
carbon
ribos
group
prevent
immun
stimul
present
either
sens
antisens
strand
vitro
figur
singl
base
uridin
modif
could
prevent
immun
stimul
sirna
duplex
form
sens
antisens
elicit
immun
stimul
figur
chemic
modifi
sirna
retain
abil
inhibit
influenza
rnai
mechan
vitro
figur
ic
duplex
subnmol
rang
nmoll
notabl
duplex
strand
exhibit
slightli
reduc
potenc
ic
approach
nmoll
though
sirna
duplex
form
heavili
substitut
rna
strand
suffer
slight
reduct
activ
subset
sirna
repres
unmodifi
chemic
modifi
duplex
retain
full
vitro
rnai
activ
select
vivo
investig
immun
stimul
antivir
activ
modifi
sequenc
incorpor
optim
formul
lyophil
nanoparticl
investig
immun
stimul
suppress
influenza
vivo
mous
model
chemic
modif
block
immun
stimul
human
pbmc
vitro
also
prevent
activ
vivo
black
swiss
mice
figur
plaqu
assay
may
confound
product
noninfecti
viral
particl
residu
cytokin
lung
sampl
toxic
thu
establish
correl
function
viral
particl
measur
plaqueform
assay
level
viral
mrna
supplementari
figur
measur
viral
mrna
level
normal
housekeep
gene
glyceraldehyd
dehydrogenas
investig
specif
inhibit
sirna
target
influenza
genom
measur
branch
dna
assay
viral
rna
level
block
immun
stimul
abrog
antivir
respons
figur
addit
chemic
modifi
sequenc
target
irrelev
gene
firefli
luciferas
formul
lyophil
particl
induc
either
signific
immun
stimul
antivir
respons
deliveri
immunostimulatori
sirna
associ
tenfold
reduct
normal
viral
mrna
level
compar
pbstreat
mice
exhibit
significantli
greater
antivir
activ
sirna
modifi
abolish
immunostimulatori
activ
data
togeth
provid
evid
replic
influenza
viru
specif
inhibit
ifn
respons
due
carriermedi
toxic
previou
work
sequenc
target
influenza
use
sequenc
control
accur
account
isrna
activ
sequenc
tabl
seem
activ
tlrmediat
ifn
respons
observ
peimedi
deliveri
sequenc
previous
found
induc
ifn
respons
although
result
indic
antivir
activ
pei
also
rel
low
commonli
use
commerci
avail
cation
lipid
transfect
agent
dotap
lipofectamin
use
investig
biolog
isrna
activ
vitro
lipidand
peibas
nanoparticl
also
report
gener
isrna
activ
vivo
demonstr
observ
antivir
properti
sirna
relat
deliverydepend
innat
immun
stimul
rather
rnaimedi
antivir
effect
first
report
knowledg
compar
isrna
activ
amongst
differ
deliveri
system
describ
effect
increas
immun
stimul
vivo
system
deliveri
isrna
molecul
develop
novel
deliveri
system
effici
deliv
sirna
immun
stimul
better
pei
figur
report
inhibit
viral
titer
approach
reduct
compar
pb
mgkg
rna
dose
reduct
mgkg
dose
use
unmodifi
sirna
lyophil
lipidoid
nanoparticl
antivir
activ
lyophil
nanoparticl
superior
pei
nanoparticl
encapsul
sirna
figur
amplifi
differ
isrna
activ
differ
sequenc
figur
note
antivir
activ
optim
lipidoidsirna
nanoparticl
limit
sequenc
previous
identifi
isrna
ref
also
exhibit
antivir
activ
although
polya
strand
sipolyau
report
induc
ifn
respons
deliv
dotap
combin
polyu
strand
lipidoid
nanoparticl
rna
also
signific
antivir
activ
figur
like
due
high
uridin
content
deliveri
lyophil
nanoparticl
preferenti
ifnproduc
cell
like
increas
isrna
potenti
given
sirna
sequenc
includ
sequenc
antivir
activ
observ
associ
effici
induct
type
ifn
respons
induct
proinflammatori
cytokin
respons
induct
figur
lipidoid
materi
capabl
mediat
cytosol
deliveri
sirna
molecul
achiev
rnai
vitro
vivo
liver
given
effici
engag
sirna
molecul
requir
endosom
local
result
indic
endosom
uptak
one
method
intern
vivo
pei
hand
highli
effici
rapid
endosom
escap
therefor
may
releas
signific
rna
endosom
interact
tlr
lyophil
lipidoid
nanoparticl
increas
particl
size
increas
antivir
activ
howev
lyophil
process
suffici
achiev
high
antivir
activ
dialysi
lyophil
result
particl
decreas
antivir
activ
supplementari
figur
dialyz
lipidoidsirna
nanoparticl
deliv
sirna
liver
spleen
albeit
without
result
rnai
spleen
hypothes
lyophil
particl
increas
particl
size
preferenti
increas
uptak
liver
splenic
pdc
understand
control
activ
immun
respons
import
step
toward
use
sirna
molecul
therapeut
observ
signific
antiflu
effect
due
rnai
larg
antivir
effect
caus
immunostimulatori
aspect
certain
sirna
sens
strand
sequenc
suggest
activ
human
pbmc
vitro
find
consist
report
sirna
duplex
contain
deoxythymidin
show
immunostimulatori
activ
vitro
human
pbmc
figur
formul
test
vivo
figur
modif
phosphorothio
linkag
also
littl
effect
sirnamedi
immun
activ
modif
abl
block
ifn
respons
vitro
vivo
accordingli
modif
block
vivo
antivir
respons
figur
previou
report
indic
minimum
two
residu
must
modifi
prevent
immun
stimul
observ
blockad
tlr
activ
modif
one
central
uridin
residu
modifi
strand
tabl
antisens
strand
sequenc
effici
prevent
ifn
respons
human
pbmc
figur
central
base
modif
also
slightli
decreas
potenc
rnai
activ
although
elimin
figur
investig
vivo
interestingli
extens
modif
multipl
base
sens
strand
molecul
chang
rnai
potenc
modif
complet
preserv
vitro
rnai
activ
directli
test
immunostimulatori
activ
sirna
isol
mous
cell
vitro
observ
similar
immunostimulatori
activ
vitro
human
pbmc
vivo
mice
consist
literatur
descript
recent
robbin
et
al
report
misinterpret
antiinfluenza
effect
sequenc
due
immun
stimul
show
sequenc
uniqu
nonstimulatori
unknown
reason
though
low
gucont
sequenc
could
factor
also
demonstr
modif
uridin
nucleotid
sens
strand
abrog
immun
respons
antivir
activ
result
present
consist
observ
differ
immunostimulatori
natur
variou
sirna
contain
report
robbin
et
al
although
demonstr
minim
modif
necessari
prevent
undesir
immun
stimul
exact
posit
number
chemic
modif
requir
abolish
immunostimul
must
test
confirm
experiment
casebycas
basi
demonstr
role
enhanc
deliveri
increas
immunostimulatori
sirna
effect
despit
evid
chemic
modifi
modifi
exhibit
potent
rnaimedi
antivir
activ
vitro
figur
without
signific
immun
stimulatori
activ
vitro
figur
vivo
figur
sirna
reduc
viru
titer
mice
deliv
lipidoid
formul
howev
use
differ
formul
previous
observ
rnaimedi
antivir
activ
follow
direct
pulmonari
instil
mous
model
rsv
infect
formul
describ
optim
maximum
prophylact
effect
due
immunostimulatori
deliveri
rna
possibl
rel
contribut
rnaimedi
gene
silenc
may
signific
deliveri
method
formul
stabli
express
capabl
knock
report
gene
express
data
shown
inhibit
influenza
viru
product
cell
cultur
lack
observ
vivo
rnai
mediat
formul
highlight
import
sirna
deliveri
achiev
desir
rnai
activ
thu
addit
develop
need
facilit
rnaimedi
antiinfluenza
activ
system
administ
vivo
immunostimul
use
sirna
potenti
benefit
well
immunostimulatori
rna
molecul
use
induc
antitumor
effect
could
serv
adjuv
gener
vaccin
respons
previous
report
reduct
viral
titer
superleth
infect
model
similar
one
describ
lead
surviv
benefit
reduct
viral
titer
approach
surviv
rate
also
investig
therapeut
model
treat
influenza
infect
nanoparticl
administ
infect
viru
howev
signific
benefit
observ
dose
scheme
supplementari
figur
still
prophylact
antivir
effect
nanoparticl
encapsul
sirna
robust
achiev
reduct
viral
titer
provid
evid
formul
method
significantli
alter
vivo
activ
unmodifi
small
rna
molecul
activ
cellspecif
compartment
late
endosom
control
deliveri
influenc
level
immunostimulatori
sirna
activ
engag
import
innat
antivir
respons
avoid
tlr
import
develop
rnai
therapi
infecti
diseas
set
addit
excess
activ
lead
increas
type
ifn
secret
pdc
associ
autoimmun
sirna
administ
vivo
must
therefor
avoid
sustain
intern
endosom
pdc
cell
sirna
must
modifi
prevent
activ
demonstr
nevertheless
attract
therapeut
potenti
use
control
sirna
deliveri
would
simultan
rnai
activ
immuno
stimulatori
rna
activ
rna
molecul
singl
rna
dual
function
may
therefor
readili
achiev
control
deliveri
cytosol
locat
rnai
activ
endosom
locat
pdc
innat
immun
activ
show
antivir
ifn
relat
cytokin
respons
mediat
certain
sirna
vivo
influenc
deliveri
materi
formul
suppress
chemic
modif
sirna
work
offer
proof
concept
optim
vivo
drug
deliveri
isrna
activ
well
evid
even
robust
deliveri
system
render
immunosil
certain
chemic
modif
sirna
unmodifi
sirna
molecul
purchas
dharmacon
lafayett
co
vivo
process
option
process
option
ref
ref
ref
sequenc
previous
report
chemic
modifi
sirna
sequenc
firefli
luciferas
sequenc
synthes
alnylam
pharmaceut
cambridg
see
tabl
sequenc
tabl
sequenc
chemic
modif
lipidoid
pei
nanoparticl
prepar
lipidoid
ref
dissolv
mgml
ethanol
cholesterol
sigmaaldrich
st
loui
mo
dissolv
mgml
ethanol
succinyl
methoxypolyethylen
glycol
mpeg
ceramid
peg
avanti
polar
lipid
alabast
al
dissolv
mgml
ethanol
lipidoid
cholesterol
peg
combin
mass
ratio
l
c
p
vortex
briefli
dilut
mixtur
ethanol
sodium
acet
mmoll
mgml
sucros
final
lipidoid
concentr
mgml
ethanol
naac
sirna
dilut
naac
mmoll
dilut
lipidoidcholesterolpeg
ad
dilut
sirna
mass
ratio
l
r
vortex
minut
allow
complex
form
complex
lipidoidrna
nanoparticl
extrud
pass
doubl
membran
whatman
florham
park
nj
northern
lipid
british
columbia
canada
extrus
system
remov
ethanol
inject
nanoparticl
dialyz
slidealyz
molecular
weight
cutoff
dialysi
cassett
pierc
biotechnolog
rockford
il
pb
lyophil
mg
sucros
ad
per
ml
extrud
complex
freez
hour
follow
daylyophil
vivo
jetpei
purchas
polyplu
new
york
ny
peisirna
complex
made
accord
manufactur
protocol
immedi
inject
dilut
pb
glucos
quantif
encapsul
effici
sirna
sampl
nanoparticl
dilut
trisedta
buffer
mix
either
trisedta
buffer
trisedta
incub
quantit
ribogreen
reagent
invitrogen
carlsbad
ca
accord
manufactur
protocol
minut
black
plate
fluoresc
intens
determin
nm
ex
nm
em
total
fluoresc
presenc
tritonx
compar
standard
curv
sirna
dilut
trisedta
determin
total
sirna
concentr
sirna
encapsul
effici
determin
ratio
fluoresc
signal
without
tritonx
signal
tritonx
nanoparticl
size
assay
light
scatter
use
zetap
instrument
brookhaven
instrument
holtsvil
ny
male
black
swiss
mice
purchas
tacon
farm
hudson
ny
care
accord
standard
massachusett
institut
technolog
guidanc
divis
compar
medicin
mice
anesthet
mixtur
ketamin
mgml
xylazin
mgml
pb
intraperiton
inject
nanoparticl
resuspend
dilut
pb
sirnaml
immedi
inject
pb
volum
equival
nanoparticl
inject
use
control
inject
made
intraven
retroorbit
plexu
mice
dose
nanoparticl
twice
hour
infect
influenza
hour
influenza
viru
dilut
plaqueform
unitsml
pb
wt
bovin
serum
albumin
uml
penicillinstreptomycin
anesthet
mice
ketamin
xylazin
mixtur
plaqueform
unit
dilut
viru
instil
intranas
dropwis
hour
hour
infect
mice
sacrif
lung
remov
whole
lung
flash
frozen
liquid
nitrogen
ml
pb
wt
bovin
serum
albumin
subject
two
freezethaw
cycl
lung
homogen
sonic
releas
viru
centrifug
rel
centrifug
forc
minut
supernat
sampl
frozen
analysi
determin
viral
titer
plaqueform
unit
assay
madindarbi
canin
kidney
cell
seed
cellswel
plate
dulbecco
modifi
eagl
medium
mmoll
hepe
fetal
bovin
serum
uml
penicillinstreptomycin
mmoll
glucos
allow
grow
singlelay
confluenc
overnight
media
aspir
well
viruscontain
sampl
serial
dilut
tenfold
pb
ad
onto
cell
triplic
follow
incub
period
period
shake
distribut
viral
particl
evenli
cell
cover
ml
semisolid
agarmedia
solut
limit
viral
particl
spread
celltocel
contact
plaqu
count
day
determin
viral
titer
viral
rna
level
whole
lung
harvest
flash
frozen
liquid
nitrogen
mechan
pulver
lung
sampl
reconstitut
pb
digest
cell
lysi
buffer
proteinas
k
epicentr
madison
wi
assay
use
branch
dna
assay
panom
fremont
ca
probe
specif
genom
rna
level
genom
measur
compar
glyceraldehyd
dehydrogenas
mrna
level
housekeep
gene
normal
vivo
cytokin
assay
mice
dose
nanoparticl
follow
similar
schedul
describ
without
influenza
infect
mice
dose
nanoparticl
twice
hour
hour
hour
second
inject
mice
kill
blood
collect
cardiac
punctur
serum
collect
follow
clot
centrifug
serum
collect
tube
sarstedt
newton
nc
sandwich
enzymelink
immunosorb
assay
use
quantifi
serum
level
pbl
laboratori
piscataway
nj
serum
level
ebiosci
san
diego
ca
vitro
cytokin
assay
human
pbmc
purifi
anonym
donor
blood
buffi
coat
institut
transfus
medicin
blood
bank
suhl
germani
densiti
centrifug
ficollhistopaqu
sigmaaldrich
munich
germani
plate
plate
cellsml
geneport
genlanti
san
diego
ca
dotap
roch
appli
scienc
indianapoli
complex
sirna
incub
nmoll
sirna
pbmc
hour
supernat
collect
assay
sandwich
enzymelink
immunosorb
assay
level
human
human
benderm
vienna
austria
vitro
rnai
assay
vero
cell
seed
cellswel
plate
incub
confluenc
cell
transfect
sirna
complex
lipofectamin
invitrogen
cell
wash
pb
hour
infect
viru
viral
titer
assay
immunostain
plaqu
assay
use
primari
antiinfluenza
antibodi
chemicon
temecula
ca
follow
fix
permeabil
cell
supplementari
materi
tabl
physic
characterist
lipidoidsirna
particl
repres
batch
figur
fold
reduct
viral
titer
due
differ
method
lipidoid
nanoparticl
formul
figur
inhibitori
effect
mismatch
sirna
control
sequenc
correl
induct
system
type
interferon
respons
figur
correl
plaqu
form
unit
pfu
assay
branch
dna
bdna
viral
mrna
assay
determin
viral
load
figur
surviv
follow
low
dose
influenza
challeng
treatment
lipidoid
nanoparticl
